Inhalative Therapie chronischer Erkrankungen der unteren Atemwege bei Hund und Katze – eine Literaturübersicht

Zusammenfassung

Chronische Atemwegserkrankungen sind prävalente Krankheiten bei Hunden und Katzen, die meist einer lebenslangen Therapie bedürfen. Grundpfeiler vieler chronisch-entzündlicher Atemwegserkrankungen stellen Glukokortikoide dar. Zum Teil wird die Therapie zur besseren Symptomkontrolle zusätzlich durch Bronchodilatatoren ergänzt.

Aufgrund des erfolgreichen Einsatzes inhalativer Glukokortikoide in der Humanmedizin und der damit verbundenen Verringerung systemischer Nebenwirkungen, gewinnt auch in der Tiermedizin die Inhalationstherapie zunehmend an Bedeutung. Hierzu werden bei Hund und Katze vor allem Inhalationskammern (engl. „Spacer“ oder „Valved Holding Chambers“) in Kombination mit Dosieraerosolen verwendet. Die technischen Eigenschaften dieser Geräte sowie ihre Handhabung und Instandhaltung werden im Folgenden aufgezeigt. Darüber hinaus soll die aktuelle Studienlage zur Anwendung und Wirksamkeit inhalativer Präparate zur Therapie chronischer Atemwegserkrankungen bei Hunden und Katzen in folgendem Artikel zusammengefasst werden.

Abstract

Chronic respiratory diseases are prevalent medical conditions in dogs and cats requiring lifelong treatment. Mainstay of therapy for chronic inflammatory respiratory diseases are glucocorticoids. Concurrent treatment with bronchodilators may be necessary to control clinical signs sufficiently. Due to the successful use in people as well as subsequent reduction of adverse effects of long-term glucocorticoid therapy, inhalative therapy has become increasingly important in veterinary medicine as well. Primarily spacers or valved holding chambers, in combination with metered dose inhalers, are used in dogs and cats. The technical properties of these devices, as well as their use and maintenance will be described in the following article. Furthermore, the existing literature regarding efficacy of inhalative medications for therapy of chronic inflammatory airway diseases in dogs and cats will be summarized.

Schlüsselwörter

Atemwegserkrankung - Glukokortikoide - Bronchodilatatoren - Inhalationstherapie - Inhalationskammern

Key words

Respiratory disease - glucocorticoids - bronchodilators - aerosol therapy - spacer devices

Publikationsverlauf

Eingereicht: 03. Mai 2022

Angenommen: 25. Juli 2022

Artikel online veröffentlicht:
06. September 2022

• Literatur

• 1 Melamies M, Vainio O, Spillmann T. et al. Endocrine effects of inhaled budesonide compared with inhaled fluticasone propionate and oral prednisolone in healthy Beagle dogs. Vet J 2012; 194: 349-353 DOI: 10.1016/j.tvjl.2012.04.029.
• 2 Reinero CR. Advances in the understanding of pathogenesis, and diagnostics and therapeutics for feline allergic asthma. Vet J 2011; 190: 28-33 DOI: 10.1016/j.tvjl.2010.09.022.
• 3 Trizil JE, Reinero CR, Trzil JE. et al. Update on Feline Asthma. Vet Clin Small Anim 2014; 44: 91-105 DOI: 10.1016/j.cvsm.2013.08.006.
• 4 McKiernan BC. Diagnosis and treatment of canine chronic bronchitis: Twenty years of experience. Vet Clin North Am – Small Anim Pract 2000; 30: 1267-1278 DOI: 10.1016/S0195-5616(00)06006-X.
• 5 Clercx C, Peeters D. Canine Eosinophilic Bronchopneumopathy. Vet Clin Small Anim 2007; 37: 917-935 DOI: 10.1016/j.cvsm.2007.05.007.
• 6 Cohn LA, DeClue AE, Cohen RL. et al. Effects of fluticasone propionate dosage in an experimental model of feline asthma. J Feline Med Surg 2010; 12: 91-96 DOI: 10.1016/j.jfms.2009.05.024.
• 7 Reinero CR, Brownlee L, Decile KC. et al. Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. J Vet Intern Med 2006; 20: 57-64 DOI: 10.1892/0891-6640(2006)20[57:IFSTHA]2.0.CO;2.
• 8 Cocayne CG, Reinero CR, DeClue AE. Subclinical airway inflammation despite high-dose oral corticosteroid therapy in cats with lower airway disease. J Feline Med Surg 2011; 13: 558-563 DOI: 10.1016/j.jfms.2011.04.001.
• 9 Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respir Med 2006; 100: 1307-1317 DOI: 10.1016/j.rmed.2005.11.020.
• 10 Lovinsky-Desir S, O’Connor GT. Evolving Strategies for Long-term Asthma Management. JAMA – J Am Med Assoc 2020; 324: 2265-2267 DOI: 10.1001/jama.2020.16895.
• 11 Rubin BK, Fink JB. The delivery of inhaled medication to the young child. Pediatr Clin North Am 2003; 50: 717-731 DOI: 10.1016/S0031-3955(03)00049-X.
• 12 Ankermann T, Brendel-Müller K, Klein MO. Medikamente zur Therapie des Asthma bronchiale im Kindesalter. 2010: 6-23
• 13 Trizil JE. Feline Asthma Diagnostic and Treatment Update. Vet Clin Small Anim 2020; 50: 375-391
• 14 McCarthy GM, Quinn PJ. Bronchoalveolar lavage in the cat: cytological findings. Can J Vet Res 1989; 53: 259-263
• 15 Grotheer M, Schulz B. Felines Asthma und chronische Bronchitis – Übersicht zu Diagnostik und Therapie Feline asthma and chronic bronchitis – an overview of diagnostics and therapy Einleitung Ätiologie und Pathophysiologie Klinische Symptomatik Diagnostische Abklärung Risikofak. Thieme 2019; 175-188
• 16 Galler A, Shibly S, Bilek A. et al. Inhaled budesonide therapy in cats with naturally occurring chronic bronchial disease (feline asthma and chronic bronchitis). J Small Anim Pract 2013; 54: 531-536 DOI: 10.1111/jsap.12133.
• 17 Adamama-Moraitou KKK, Patsikas MNN, Koutinas AFF. Feline lower airway disease: a retrospective studyof 22 naturally occurring cases from Greece. J Feline Med Surg 2004; 6: 227-233 DOI: 10.1016/j.jfms.2003.09.004.
• 18 Leemans J, Kirschvink N, Clercx C. et al. Functional response to inhaled salbutamol and/or ipratropium bromide in Ascaris suum-sensitised cats with allergen-induced bronchospasms. Vet J 2010; 186: 76-83 DOI: 10.1016/j.tvjl.2009.07.021.
• 19 Garrity S, Lee-Fowler T, Reinero C. Feline asthma and heartworm disease: Clinical features, diagnostics and therapeutics. J Feline Med Surg 2019; 21: 825-834 DOI: 10.1177/1098612X18823348.
• 20 Padrid P. Feline asthma: Diagnosis and treatment. Vet Clin North Am – Small Anim Pract 2000; 30: 1279-1293 DOI: 10.1016/S0195-5616(00)06007-1.
• 21 Padrid PA, Hornof WJ, Kurpershoek CJ. et al. Canine Chronic Bronchitis A Pathophysiologic Evaluation of 18 Cases. J Vet Intern Med 1990; 4: 172-180
• 22 Johnson LR. Exacerbations of Chronic Bronchitis. In: Drobatz KJ, Hopper K, Rozanski E. et al. Hrsg. Textbook of Small Animal Emergency Medicine. John Wiley & Sons, Inc.; 2019: 215-210 www.wiley.com/go/drobatz/textbook
• 23 Dhillon KS, Kaur SJ. Diagnosis and management of canine chronic bronchitis : A review. J Entomol Zool Stud 2020; 8: 1102-1105
• 24 Johnson LR, Johnson EG, Hulsebosch SE. et al. Eosinophilic bronchitis, eosinophilic granuloma, and eosinophilic bronchopneumopathy in 75 dogs (2006–2016). J Vet Intern Med 2019; 33: 2217-2226 DOI: 10.1111/jvim.15605.
• 25 Casamian-Sorrosal D, Silvestrini P, Blake R. et al. Clinical features and long-term follow-up of 70 cases of canine idiopathic eosinophilic lung disease. Vet Rec 2020; 187: 14-17 DOI: 10.1136/vr.105193.
• 26 Clercx C, Peeters D, Snaps F. et al. Eosinophilic Bronchopneumopathy in Dogs. J Vet Intern Med 2000; 14: 282-291
• 27 Canonne AM, Bolen G, Peeters D. et al. Long-term follow-up in dogs with idiopathic eosinophilic bronchopneumopathy treated with inhaled steroid therapy. J Small Anim Pract 2016; 57: 537-542 DOI: 10.1111/jsap.12529.
• 28 Venema C, Patterson C. Feline Asthma – What´s new and where might clinical practice be heading?. J Feline Med Surg 2010; 12: 681-692
• 29 Reinero CR. Feline asthma. In: Noli C, Foster A, Rosenkrantz W. Hrsg. Veterinary Allergy. John Wiley & Sons, Ltd.; 2014: 239-245
• 30 Rozanski EA, Bach JF, Shaw SPP. Advances in Respiratory Therapy. Vet Clin North Am – Small Anim Pract 2007; 37: 963-974 DOI: 10.1016/j.cvsm.2007.05.009.
• 31 Leemans J, Kirschvink N, Bernaerts F. et al. A pilot study comparing the antispasmodic effects of inhaled salmeterol, salbutamol and ipratropium bromide using different aerosol devices on muscarinic bronchoconstriction in healthy cats. Vet J 2009; 180: 236-245 DOI: 10.1016/j.tvjl.2007.11.008.
• 32 Kirschvink N, Leemans J, Delvaux F. et al. Inhaled fluticasone reduces bronchial responsiveness and airway inflammation in cats with mild chronic bronchitis. J Feline Med Surg 2006; 8: 45-54 DOI: 10.1016/j.jfms.2005.07.001.
• 33 Mardell E. Investigation and treatment of feline chronic bronchial disease. In Pract 2007; 29: 138-146 DOI: 10.1136/inpract.29.3.138.
• 34 Rieder J, Mischke R. Immunsuppressive Therapie bei Hunden und Katzen. Tierärztliche Prax Kleintiere 2018; 2: 105-118
• 35 Behrend EN, Kemppainen RJ. Glucocorticoid therapy: Pharmacology, indications, and complications. Vet Clin North Am – Small Anim Pract 1997; 27: 187-213 DOI: 10.1016/S0195-5616(97)50027-1.
• 36 Plumb DC. Plumb’s Veterinary Drug Handbook. 7. Aufl.. Stockholm, Wisconsin: PharmaVet Inc.; 2011
• 37 Lowe AD, Campbell KL, Graves T. Glucocorticoids in the cat. Vet Dermatol 2008; 19: 340-347 DOI: 10.1111/j.1365-3164.2008.00717.x.
• 38 Bexfield NH, Foale RD, Davison LJ. et al. Management of 13 cases of canine respiratory disease using inhaled corticosteroids. J Small Anim Pract 2006; 47: 377-382 DOI: 10.1111/j.1748-5827.2006.00028.x.
• 39 Cohn LA, DeClue AE, Reinero CR. Endocrine and Immunologic Effects of Inhaled Fluticasone Propionate in Healthy Dogs. J Vet Intern Med 2008; 22: 37-43 DOI: 10.1111/j.1939-1676.2007.0011.x.
• 40 Nelson RW, Couto CG. Innere Medizin der Kleintiere. 2. Aufl.. München: Elsevier, Urban & Fischer Verlag; 2010
• 41 Smith SA, Tobias AH, Fine DM. et al. Corticosteroid-Associated Congestive Heart Failure in 12 Cats. Int J Appl Res Vet Med 2004; 2: 159-170
• 42 Ployngam T, Tobias AH, Smith SA. et al. Hemodynamic effects of methylprednisolone acetate administration in cats. Am J Vet Res 2006; 67: 583-587 DOI: 10.2460/ajvr.67.4.583.
• 43 Masters AK, Berger DJ, Ware WA. et al. Effects of short-term anti-inflammatory glucocorticoid treatment on clinicopathologic, echocardiographic, and hemodynamic variables in systemically healthy dogs. Am J Vet Res 2018; 79: 411-423 DOI: 10.2460/ajvr.79.4.411.
• 44 Oyola MG, Handa RJ. Hypothalamic–pituitary–adrenal and hypothalamic–pituitary–gonadal axes: sex differences in regulation of stress responsivity. Stress 2017; 20: 476-494 DOI: 10.1080/10253890.2017.1369523.
• 45 Zöllner EW. Hypothalamic-pituitary-adrenal axis suppression in asthmatic children on inhaled corticosteroids: Part 1. Which test should be used?. Pediatr Allergy Immunol 2007; 18: 401-409 DOI: 10.1111/j.1399-3038.2007.00540.x.
• 46 Creedon JMB. Controversies surrounding critical illness-related corticosteroid insufficiency in animals. J Vet Emerg Crit Care 2015; 25: 107-112 DOI: 10.1111/vec.12270.
• 47 Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 2005; 25: 469-488 DOI: 10.1016/j.iac.2005.05.004.
• 48 Pedersen S. Clinical safety of inhaled corticosteroids for asthma in children: An update of long-term trials. Drug Saf 2006; 29: 599-612 DOI: 10.2165/00002018-200629070-00005.
• 49 Pescollderungg L, Radetti G, Gottardi E. et al. Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test. DOI: 10.1136/thorax.58.3.227
• 50 Chang C hoon, Cohn LA, DeClue AE. et al. Oral glucocorticoids diminish the efficacy of allergen-specific immunotherapy in experimental feline asthma. Vet J 2013; 197: 268-272 DOI: 10.1016/j.tvjl.2013.01.008.
• 51 Hess DR. Aerosol delivery devices in the treatment of asthma. Respir Care 2008; 53: 699-723
• 52 Byers CG, Dhupa N. Feline bronchial asthma: Treatment. Compend Contin Educ Pract Vet 2005; 27: 426-432
• 53 Hochhaus G. New developments in corticosteroids. Proc Am Thorac Soc 2004; 1: 269-274 DOI: 10.1513/pats.200402-007MS.
• 54 Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91: 22-28 DOI: 10.1016/S0954-6111(97)90102-5.
• 55 Brus R. Effects of High-Dose Inhaled Corticosteroids on Plasma Cortisol Concentrations in Healthy Adults. Arch Intern Med 1999; 159: 1903-1908
• 56 Daley-Yates PT, Price AC, Sisson JR. et al. Beclomethasone dipropionate: Absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51: 400-409 DOI: 10.1046/j.0306-5251.2001.01374.x.
• 57 Johnson M, Glaxo F. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 1996; 97: 169-176
• 58 Sim D, Griffiths A, Armstrong D. et al. Adrenal suppression from high-dose inhaled fluticasone propionate in children with asthma. Eur Respir J 2003; 21: 633-636 DOI: 10.1183/09031936.03.00306302.
• 59 Högger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602 DOI: 10.1016/0039-128X(94)90054-X.
• 60 Reinero CR, Decile KC, Byerly JR. et al. Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma. Am J Vet Res 2005; 66: 1121-1127 DOI: 10.2460/ajvr.2005.66.1121.
• 61 Leemans J, Kirschvink N, Clercx C. et al. Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model. Vet J 2012; 192: 41-48 DOI: 10.1016/j.tvjl.2011.01.020.
• 62 McIvor RA, Devlin HM, Kaplan A. Optimizing the delivery of inhaled medication for respiratory patients: The role of valved holding chambers. Can Respir J 2018; 2018 DOI: 10.1155/2018/5076259.
• 63 Laube BL, Janssens HM, De Jongh FHC. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-1331 DOI: 10.1183/09031936.00166410.
• 64 Lavorini F, Fontana GA. Targeting drugs to the airways: The role of spacer devices. Expert Opin Drug Deliv 2009; 6: 91-102 DOI: 10.1517/17425240802637862.
• 65 Vargo CL, Banovic F. Localized Demodicosis in a Dog After Fluticasone Propionate Treatment for Chronic Bronchitis. Top Companion Anim Med 2021; 45: 100578 DOI: 10.1016/j.tcam.2021.100578.
• 66 Bizikova P. Localized demodicosis due to Demodex cati on the muzzle of two cats treated with inhalant glucocorticoids. 2014 DOI: 10.1111/vde.12123
• 67 Hirt RA. Felines Asthma bronchiale – Überblick und neue. 2003 90. 110-123
• 68 Bolognin M, Kirschvink N, Leemans J. et al. Characterisation of the acute and reversible airway inflammation induced by cadmium chloride inhalation in healthy dogs and evaluation of the effects of salbutamol and prednisolone. Vet J 2009; 179: 443-450 DOI: 10.1016/j.tvjl.2007.10.004.
• 69 De Simoi V, Schulz B. Canine eosinophilic bronchopneumopathy. Kleintierpraxis 2018; 63: 475-488 DOI: 10.2377/0023-2076-63-475.
• 70 Kirschvink N, Leemans J, Delvaux F. et al. Bronchodilators in bronchoscopy-induced airflow limitation in allergen-sensitized cats. J Vet Intern Med 2005; 19: 161-167 DOI: 10.1892/0891–6640(2005)19 < 161:BIBALI > 2.0.CO;2L42:URLEND.
• 71 Fernández-Parra R, Pey P, Reinero C. et al. Salbutamol Transport and Deposition in the Upper and Lower Airway with Different Devices in Cats : A Computational Fluid Dynamics Approach. Animals 2021; 11: 1-20
• 72 Reinero CR, Delgado C, Spinka C. et al. Enantiomer-specific effects of albuterol on airway inflammation in healthy and asthmatic cats. Int Arch Allergy Immunol 2009; 150: 43-50 DOI: 10.1159/000210379.
• 73 Dhand R, Goode M, Reid R. et al. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med 1999; 160: 1136-1141 DOI: 10.1164/ajrccm.160.4.9812074.
• 74 Keir S, Page C, Spina D. Bronchial hyperresponsiveness induced by chronic treatment with albuterol: Role of sensory nerves. J Allergy Clin Immunol 2002; 110: 388-394 DOI: 10.1067/mai.2002.126661.
• 75 Cugell DW. Clinical pharmacology and toxicology of ipratropium bromide. Am J Med 1986; 81: 18-22 DOI: 10.1016/0002-9343(86)90457-2.
• 76 Kips JC, O’Connor BJ, Inman MD. et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161: 996-1001 DOI: 10.1164/ajrccm.161.3.9812056.
• 77 Eickelberg O, Roth M, Lörx R. et al. Ligand-independent activation of the glucocorticoid receptor by β2- adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274: 1005-1010 DOI: 10.1074/jbc.274.2.1005.
• 78 Chung KF. The complementary role of ducocorticosteroids and long-acting β-adrenergic agonists. Allergy Eur J Allergy Clin Immunol 1998; 53: 7-13 DOI: 10.1111/j.1398-9995.1998.tb04887.x.
• 79 Geller DE. Comparing Clinical Features of the Nebulizer, Metered-Dose Inhaler, and Dry Powder Inhaler. Respir Care 2005; 50: 1313-1321 DOI: 10.1006/geno.1995.1140.
• 80 Wildhaber JH, Dore ND, Wilson JM. et al. Inhalation therapy in asthma: Nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28-33 DOI: 10.1016/S0022-3476(99)70323-9.
• 81 Dolovich MB, Ahrens RC, Hess DR. et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335-371 DOI: 10.1378/chest.127.1.335.
• 82 Chow KE, Tyrrell D, Yang M. et al. Scintigraphic Assessment of Deposition of Radiolabeled Fluticasone Delivered from a Nebulizer and Metered Dose Inhaler in 10 Healthy Dogs. J Vet Intern Med 2017; 31: 1849-1857 DOI: 10.1111/jvim.14832.
• 83 Hunt LW, Frigas E, Butterfield JH. et al. Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study. J Allergy Clin Immunol 2004; 113: 853-859 DOI: 10.1016/j.jaci.2004.02.039.
• 84 Ohnishi T, Kita H, Mayeno AN. et al. Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines. Clin Exp Immunol 1996; 104: 325-331 DOI: 10.1046/j.1365-2249.1996.32737.x.
• 85 Decco ML, Neeno TA, Hunt LW. et al. Nebulized lidocaine in the treatment of severe asthma in children: A pilot study. Ann Allergy, Asthma Immunol 1999; 82: 29-32 DOI: 10.1016/S1081–1206(10)62656–7.
• 86 Nafe LA, Guntur VP, Dodam JR. et al. Nebulized lidocaine blunts airway hyper-responsiveness in experimental feline asthma. J Feline Med Surg 2013; 15: 712-716 DOI: 10.1177/1098612X13476705.
• 87 Kwok PCL, Chan H-K. Delivery of inhalation drugs to children for asthma and other respiratory diseases. Adv Drug Deliv Rev 2014; 73: 83-88 DOI: 10.1016/j.addr.2013.11.007.
• 88 Levison H, Children S. PEDIATRIC PHARMACOLOGY AND THERAPEUTICS Nebulized albuterol in a c u t e bronchiolitis. History 1990; 2-6
• 89 Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): A review of causes of inconsistent medication delivery. Prim Care Respir J 2007; 16: 207-214 DOI: 10.3132/pcrj.2007.00034.
• 90 Vincken W, Levy ML, Scullion J. et al. Spacer devices for inhaled therapy: why use them, and how?. ERJ Open Res 2018; 4: 00065-02018 DOI: 10.1183/23120541.00065-2018.
• 91 Grossman J. The evolution of inhaler technology. J Asthma 1994; 31: 55-64 DOI: 10.3109/02770909409056770.
• 92 Newman SP, Millar AB, Lennard-Jones TR. et al. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39: 935-941 DOI: 10.1136/thx.39.12.935.
• 93 Rubin BK, Fink JB. Optimizing aerosol delivery by pressurized metered-dose inhalers. Respir Care 2005; 50: 1191-1197
• 94 Cohen HA, Cohen Z, Pomeranz AS. et al. Bacterial Contamination of Spacer Devices Used by Asthmatic Children. J Asthma 2005; 42: 169-172 DOI: 10.1081/jas-54625.
• 95 Nikander K, Nicholls C, Denyer J. et al. The evolution of spacers and valved holding chambers. J Aerosol Med Pulm Drug Deliv 2014; 27 DOI: 10.1089/jamp.2013.1076.
• 96 Amirav I, Newhouse MT. Review of optimal characteristics of face-masks for Valved-Holding Chambers (VHCs). Pediatr Pulmonol 2008; 43: 268-274 DOI: 10.1002/ppul.20767.
• 97 Carranza Valencia A, Hirt R, Kampner D. et al. Comparison of pulmonary deposition of nebulized 99 m technetium-diethylenetriamine-pentaacetic acid through 3 inhalation devices in healthy dogs. J Vet Intern Med 2021; 35: 1080-1087 DOI: 10.1111/jvim.16064.
• 98 Trudell Medical International. AeroKat* für Katzen | Hat Ihre Katze felines Asthma?. Im Internet: Zugriff am 05. Juli 2021 unter: https://aerochamber.at/aerokat-fuer-katzen/
• 99 Cegla Medizintechnik. RC-Animal-Chamber HUND | Inhalierhilfe für Tiere. Im Internet: Zugriff am 05. Juli 2021 unter: https://www.cegla.de/produkte/tiermedizin/rc-animal-chamber-hund
• 100 International Cat Care. Inhaler Training. 2022. Im Internet: https://icatcare.org/inhaler-training/
• 101 Piérart F, Wildhaber J, Vrancken I. et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur Respir J 1999; 13: 673-678
• 102 O’Malley CA. Device cleaning and infection control in aerosol therapy. Respir Care 2015; 60: 917-930 DOI: 10.4187/respcare.03513.
• 103 Tay ET, Needleman JP, Avner JR. Nebulizer and spacer device maintenance in children with asthma. J Asthma 2009; 46: 153-155 DOI: 10.1080/02770900802538244.
• 104 Riquena B, Velloso Monte LDF, Lopes AJ. et al. Microbiological contamination of nebulizers used by cystic fibrosis patients: An underestimated problem. J Bras Pneumol 2019; 45: 1-9 DOI: 10.1590/1806-3713/e20170351.
• 105 Cohen HA, Kahan E, Cohen Z. et al. Microbial colonization of nebulizers used by asthmatic children. Pediatr Int 2006; 48: 454-458 DOI: 10.1111/j.1442-200X.2006.02252.x.
• 106 Vassal S, Taamma R, Marty N. et al. Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis. Am J Infect Control 2000; 28: 347-351 DOI: 10.1067/mic.2000.110214.
• 107 Ohki M, Hyo Y, Yoshiyama Y. et al. Consensus guidance of nebulizer therapy for acute rhinosinusitis. Auris Nasus Larynx 2020; 47: 18-24 DOI: 10.1016/j.anl.2019.08.007.
• 108 De Vries TW, Rienstra SR, Van Der Vorm ER. Bacterial contamination of inhalation chambers: Results of a pilot study. J Aerosol Med Depos Clear Eff Lung 2004; 17: 354-356 DOI: 10.1089/jam.2004.17.354.
• 109 Cegla Medizintechnik. Reinigungs-und Desinfektionsanleitung RC-Animal Chamber. Im Internet: Zugriff am 05. Juli 2021 unter: https://www.cegla.de/files/downloads/manuals/RC-Animal-Chamber-manual-de.pdf
• 110 Trudell Medical International. Gebrauchsinformation AeroChamber. Im Internet: Zugriff am 05. Juli 2021 unter: https://aerochamber.at/wp-content/uploads/2020/09/Gebrauchsinformation-AeroChamber-2020-print.pdf
• 111 Zuana A Della, Garcia D de O, Juliani RCTP. et al. Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers. J Bras Pneumol 2014; 40: 119-127 DOI: 10.1590/s1806-37132014000200004.
• 112 Klenk FK, DeSimoi V, Wolf G. et al. Evaluation of different cleaning methods for feline inhalation chambers after bacterial contamination. J Feline Med Surg 2021; 23: 181-184 DOI: 10.1177/1098612X20913352.